PreveCeutical Announces Rescheduled Date for Annual General and Special Meeting
PreveCeutical Medical (OTCQB: PRVCF) has rescheduled its annual general and special meeting from August 15 to September 5, 2025. At the meeting, shareholders will vote on key matters including director elections and the appointment of Davidson & Company LLP as auditors.
A significant proposal involves the distribution of up to 12 million common shares of BioGene Therapeutics to PreveCeutical shareholders through a plan of arrangement. This strategic move will result in shareholders owning stakes in both companies: BioGene, focusing on Dual Gene Therapy development, and PreveCeutical, continuing its work on preventive and curative therapies using organic products.
PreveCeutical Medical (OTCQB: PRVCF) ha posticipato la sua assemblea generale annuale e straordinaria dal 15 agosto al 5 settembre 2025. Durante l'incontro, gli azionisti voteranno su questioni fondamentali, tra cui l'elezione dei direttori e la nomina di Davidson & Company LLP come revisori dei conti.
Una proposta importante riguarda la distribuzione fino a 12 milioni di azioni ordinarie di BioGene Therapeutics agli azionisti di PreveCeutical tramite un piano di riorganizzazione. Questa mossa strategica permetterà agli azionisti di detenere partecipazioni in entrambe le società: BioGene, specializzata nello sviluppo di terapie geniche duali, e PreveCeutical, che prosegue il suo lavoro su terapie preventive e curative basate su prodotti organici.
PreveCeutical Medical (OTCQB: PRVCF) ha reprogramado su junta general anual y extraordinaria del 15 de agosto al 5 de septiembre de 2025. En la reunión, los accionistas votarán sobre asuntos clave, incluyendo la elección de directores y el nombramiento de Davidson & Company LLP como auditores.
Una propuesta significativa implica la distribución de hasta 12 millones de acciones ordinarias de BioGene Therapeutics a los accionistas de PreveCeutical mediante un plan de reorganización. Este movimiento estratégico permitirá que los accionistas posean participaciones en ambas compañías: BioGene, centrada en el desarrollo de terapia génica dual, y PreveCeutical, que continúa su trabajo en terapias preventivas y curativas basadas en productos orgánicos.
PreveCeutical Medical (OTCQB: PRVCF)는 연례 일반 및 특별 주주총회를 8월 15일에서 2025년 9월 5일로 연기했습니다. 회의에서 주주들은 이사 선출과 Davidson & Company LLP의 감사인 임명 등 주요 안건에 대해 투표할 예정입니다.
중요한 제안 중 하나는 BioGene Therapeutics의 보통주 최대 1,200만 주를 PreveCeutical 주주들에게 배분하는 계획입니다. 이 전략적 조치는 주주들이 두 회사에 모두 지분을 보유하게 하며, BioGene은 이중 유전자 치료 개발에 집중하고 PreveCeutical은 유기농 제품을 활용한 예방 및 치료용 치료제를 계속 개발할 것입니다.
PreveCeutical Medical (OTCQB : PRVCF) a reporté son assemblée générale annuelle et extraordinaire du 15 août au 5 septembre 2025. Lors de cette réunion, les actionnaires voteront sur des points clés, notamment l'élection des administrateurs et la nomination de Davidson & Company LLP en tant qu’auditeurs.
Une proposition importante concerne la distribution pouvant aller jusqu'à 12 millions d’actions ordinaires de BioGene Therapeutics aux actionnaires de PreveCeutical via un plan d’arrangement. Cette démarche stratégique permettra aux actionnaires de détenir des participations dans les deux sociétés : BioGene, spécialisée dans le développement de thérapies géniques doubles, et PreveCeutical, qui poursuit ses travaux sur des thérapies préventives et curatives utilisant des produits biologiques.
PreveCeutical Medical (OTCQB: PRVCF) hat seine jährliche Haupt- und Sonderversammlung vom 15. August auf den 5. September 2025 verschoben. Bei der Versammlung werden die Aktionäre über wichtige Angelegenheiten abstimmen, darunter die Wahl der Direktoren und die Ernennung von Davidson & Company LLP als Wirtschaftsprüfer.
Ein bedeutender Vorschlag umfasst die Verteilung von bis zu 12 Millionen Stammaktien von BioGene Therapeutics an die PreveCeutical-Aktionäre im Rahmen eines Umstrukturierungsplans. Dieser strategische Schritt ermöglicht es den Aktionären, Anteile an beiden Unternehmen zu halten: BioGene, das sich auf die Entwicklung der Dual-Gentherapie konzentriert, und PreveCeutical, das seine Arbeit an präventiven und kurativen Therapien mit organischen Produkten fortsetzt.
- Strategic separation will allow both companies to access targeted capital more effectively
- Shareholders will receive shares in two distinct companies, potentially increasing value
- Focused business models may improve operational efficiency for both entities
- Corporate restructuring may create additional administrative costs
- Potential dilution of management focus across two separate entities
Vancouver, British Columbia--(Newsfile Corp. - July 9, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, further to its News Release of June 25, 2025, it has rescheduled its annual general and special meeting from August 15, 2025 to September 5, 2025 at which the shareholders (the "PreveCeutical Shareholders") of the Company will be asked to approve:
the election of Stephen Van Deventer, Makarand Jawadekar, Linnéa Olofsson, Kathleen Rokita and C. Evan Ballantyne as directors of the Company;
the ratification of the appointment of Davidson & Company LLP, Chartered Professional Accountants, as the auditors of PreveCeutical for the financial year ending December 31, 2024 and 2025;
a plan of arrangement under the provisions of Division 5 of Part 9 of the Business Corporations Act (British Columbia), pursuant to which the Company will distribute up to 12,000,000 common shares of BioGene Therapeutics Inc. ("BioGene") to the PreveCeutical Shareholders; (the "Arrangement and Distribution") and
the adoption of the PreveCeutical's Omnibus Equity Incentive Plan.
Once the Arrangement and Distribution is complete, the PreveCeutical Shareholders will own shares in two companies: BioGene, which will focus on the development of the Dual Gene Therapy program, and PreveCeutical, which will continue to focus on developing innovative options for preventive and curative therapies utilizing organic and nature identical products.
PreveCeutical believes that the Arrangement and Distribution is in the best interests of PreveCeutical and the PreveCeutical Shareholders for numerous reasons, including that separating PreveCeutical and BioGene will expand both PreveCeutical's and BioGene's potential shareholder base and access to capital for research, development and clinical trials by allowing investors that want specific ownership in the particular business of BioGene the opportunity to invest directly in BioGene rather than through PreveCeutical.
About PreveCeutical
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit www.PreveCeutical.com, follow us on Twitter: http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.
On behalf of the Board of Directors of PreveCeutical
Stephen Van Deventer, Chairman and Chief Executive Officer
For further information, please contact:
Stephen Van Deventer: +1 604 306 9669
Or Investor Relations
ir@preveceutical.com
Neither the CSE nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/258234
FAQ
When is PreveCeutical's (PRVCF) rescheduled annual general meeting in 2025?
How many BioGene Therapeutics shares will PRVCF shareholders receive in the distribution?
What will be the focus of BioGene Therapeutics after the separation from PRVCF?
What will PreveCeutical Medical focus on after the BioGene separation?
Who are the proposed directors for PreveCeutical's board?
